Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.
Partial responses observed in 5 of 19 evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib in heavily pretreated populationPartial response observed in 1 of. | May 25, 2023
eFFECTOR Therapeutics (EFTR) Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib (ZFA triplet) in.
09.05.2023 - Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast Cancer to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 .